Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (4)

1

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma : importance of immunoglobulin supplementation

enthalten in: Blood advances | 2024

von Frerichs, K. | Verkleij, C. | Mateos, M. | +21

2

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

enthalten in: Blood advances | 2021

von Frerichs, K. | Minnema, M. | Levin, M. | +11

3

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

enthalten in: Blood advances | 2021

von Verkleij, C. | Broekmans, M. | van Duin, M. | +15

4

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

enthalten in: Blood advances | 2017

von Casneuf, T. | Xu, X. | Adams, H. | +11

1
[1]